TY - JOUR AU - Younossi, Z. M. AU - Koenig, A. B. AU - Abdelatif, D. PY - 2016 DA - 2016// TI - Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes JO - Hepatology VL - 64 UR - https://doi.org/10.1002/hep.28431 DO - 10.1002/hep.28431 ID - Younossi2016 ER - TY - JOUR AU - Matteoni, C. A. AU - Younossi, Z. M. AU - Gramlich, T. PY - 1999 DA - 1999// TI - Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity JO - Gastroenterology VL - 116 UR - https://doi.org/10.1016/S0016-5085(99)70506-8 DO - 10.1016/S0016-5085(99)70506-8 ID - Matteoni1999 ER - TY - JOUR AU - Younossi, Z. M. AU - Blissett, D. AU - Blissett, R. PY - 2016 DA - 2016// TI - The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe JO - Hepatology VL - 64 UR - https://doi.org/10.1002/hep.28785 DO - 10.1002/hep.28785 ID - Younossi2016 ER - TY - JOUR AU - Chalasani, N. AU - Younossi, Z. AU - Lavine, J. E. PY - 2012 DA - 2012// TI - The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association JO - Hepatology VL - 55 UR - https://doi.org/10.1002/hep.25762 DO - 10.1002/hep.25762 ID - Chalasani2012 ER - TY - JOUR AU - Stepanova, M. AU - Younossi, Z. M. PY - 2012 DA - 2012// TI - Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population JO - Clin Gastroenterol Hepatol VL - 10 UR - https://doi.org/10.1016/j.cgh.2011.12.039 DO - 10.1016/j.cgh.2011.12.039 ID - Stepanova2012 ER - TY - JOUR AU - Hossain, N. AU - Afendy, A. AU - Stepanova, M. PY - 2009 DA - 2009// TI - Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease JO - Clin Gastroenterol Hepatol VL - 7 UR - https://doi.org/10.1016/j.cgh.2009.06.007 DO - 10.1016/j.cgh.2009.06.007 ID - Hossain2009 ER - TY - JOUR AU - McPherson, S. AU - Hardy, T. AU - Henderson, E. PY - 2015 DA - 2015// TI - Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management JO - J Hepatol VL - 62 UR - https://doi.org/10.1016/j.jhep.2014.11.034 DO - 10.1016/j.jhep.2014.11.034 ID - McPherson2015 ER - TY - JOUR AU - Gramlich, T. AU - Kleiner, D. E. AU - McCullough, A. J. PY - 2004 DA - 2004// TI - Pathologic features associated with fibrosis in nonalcoholic fatty liver disease JO - Hum Pathol VL - 35 UR - https://doi.org/10.1016/j.humpath.2003.09.018 DO - 10.1016/j.humpath.2003.09.018 ID - Gramlich2004 ER - TY - JOUR AU - Younossi, Z. M. AU - Stepanova, M. AU - Rafiq, N. PY - 2011 DA - 2011// TI - Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality JO - Hepatology VL - 53 UR - https://doi.org/10.1002/hep.24268 DO - 10.1002/hep.24268 ID - Younossi2011 ER - TY - JOUR AU - Stepanova, M. AU - Rafiq, N. AU - Makhlouf, H. PY - 2013 DA - 2013// TI - Predictors of all-cause mortality and liver-related mortality in patients with non-alcoholic fatty liver disease (NAFLD) JO - Dig Dis Sci VL - 58 UR - https://doi.org/10.1007/s10620-013-2743-5 DO - 10.1007/s10620-013-2743-5 ID - Stepanova2013 ER - TY - JOUR AU - Younossi, Z. M. AU - Otgonsuren, M. AU - Venkatesan, C. PY - 2013 DA - 2013// TI - In patients with non-alcoholic fatty liver disease, metabolically abnormal individuals are at a higher risk for mortality while metabolically normal individuals are not JO - Metabolism VL - 62 UR - https://doi.org/10.1016/j.metabol.2012.08.005 DO - 10.1016/j.metabol.2012.08.005 ID - Younossi2013 ER - TY - STD TI - Dulai PS, Singh S, Patel J, Soni M, Prokop LJ, Younossi Z, Sebastiani G, Ekstedt M, Hagstrom H, Nasr P, Stal P, Wong VW, Kechagias S, Hultcrantz R, Loomba R. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis. Hepatology. 2017;65(5):1557–65. ID - ref12 ER - TY - JOUR AU - Ekstedt, M. AU - Hagstrom, H. AU - Nasr, P. PY - 2015 DA - 2015// TI - Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up JO - Hepatology VL - 61 UR - https://doi.org/10.1002/hep.27368 DO - 10.1002/hep.27368 ID - Ekstedt2015 ER - TY - JOUR AU - Nalbantoglu, I. L. AU - Brunt, E. M. PY - 2014 DA - 2014// TI - Role of liver biopsy in nonalcoholic fatty liver disease JO - World J Gastroenterol VL - 20 ID - Nalbantoglu2014 ER - TY - JOUR AU - Kleiner, D. E. AU - Bedossa, P. PY - 2015 DA - 2015// TI - Liver histology and clinical trials for nonalcoholic steatohepatitis-perspectives from 2 pathologists JO - Gastroenterology VL - 149 UR - https://doi.org/10.1053/j.gastro.2015.09.015 DO - 10.1053/j.gastro.2015.09.015 ID - Kleiner2015 ER - TY - JOUR AU - Sanyal, A. J. AU - Friedman, S. L. AU - McCullough, A. J. PY - 2015 DA - 2015// TI - Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop JO - Hepatology VL - 61 UR - https://doi.org/10.1002/hep.27678 DO - 10.1002/hep.27678 ID - Sanyal2015 ER - TY - JOUR AU - Degertekin, B. AU - Ozenirler, S. AU - Elbeg, S. PY - 2007 DA - 2007// TI - The serum endothelin-1 level in steatosis and NASH, and its relation with severity of liver fibrosis JO - Dig Dis Sci VL - 52 UR - https://doi.org/10.1007/s10620-006-9147-8 DO - 10.1007/s10620-006-9147-8 ID - Degertekin2007 ER - TY - JOUR AU - Ratziu, V. AU - Massard, J. AU - Charlotte, F. PY - 2006 DA - 2006// TI - Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease JO - BMC Gastroenterol VL - 6 UR - https://doi.org/10.1186/1471-230X-6-6 DO - 10.1186/1471-230X-6-6 ID - Ratziu2006 ER - TY - JOUR AU - Choe, Y. G. AU - Jin, W. AU - Cho, Y. K. PY - 2013 DA - 2013// TI - Apolipoprotein B/AI ratio is independently associated with non-alcoholic fatty liver disease in nondiabetic subjects JO - J Gastroenterol Hepatol VL - 28 UR - https://doi.org/10.1111/jgh.12077 DO - 10.1111/jgh.12077 ID - Choe2013 ER - TY - JOUR AU - Miller, M. H. AU - Walsh, S. V. AU - Atrih, A. PY - 2014 DA - 2014// TI - Serum proteome of nonalcoholic fatty liver disease: a multimodal approach to discovery of biomarkers of nonalcoholic steatohepatitis JO - J Gastroenterol Hepatol VL - 29 UR - https://doi.org/10.1111/jgh.12614 DO - 10.1111/jgh.12614 ID - Miller2014 ER - TY - JOUR AU - Younossi, Z. M. AU - Baranova, A. AU - Ziegler, K. PY - 2005 DA - 2005// TI - A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease JO - Hepatology VL - 42 UR - https://doi.org/10.1002/hep.20838 DO - 10.1002/hep.20838 ID - Younossi2005 ER - TY - JOUR AU - Baranova, A. AU - Liotta, L. AU - Petricoin, E. PY - 2007 DA - 2007// TI - The role of genomics and proteomics: technologies in studying non-alcoholic fatty liver disease JO - Clin Liver Dis VL - 11 UR - https://doi.org/10.1016/j.cld.2007.02.003 DO - 10.1016/j.cld.2007.02.003 ID - Baranova2007 ER - TY - JOUR AU - Younossi, Z. M. AU - Baranova, A. AU - Stepanova, M. PY - 2010 DA - 2010// TI - Phosphoproteomic biomarkers predicting histologic nonalcoholic steatohepatitis and fibrosis JO - J Proteome Res VL - 9 UR - https://doi.org/10.1021/pr100069e DO - 10.1021/pr100069e ID - Younossi2010 ER - TY - JOUR AU - Page, S. AU - Birerdinc, A. AU - Estep, M. PY - 2013 DA - 2013// TI - Knowledge-based identification of soluble biomarkers: hepatic fibrosis in NAFLD as an example JO - PloS one VL - 8 UR - https://doi.org/10.1371/journal.pone.0056009 DO - 10.1371/journal.pone.0056009 ID - Page2013 ER - TY - JOUR AU - Angulo, P. AU - Hui, J. M. AU - Marchesini, G. PY - 2007 DA - 2007// TI - The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD JO - Hepatology VL - 45 UR - https://doi.org/10.1002/hep.21496 DO - 10.1002/hep.21496 ID - Angulo2007 ER - TY - JOUR AU - Guha, I. N. AU - Parkes, J. AU - Roderick, P. PY - 2008 DA - 2008// TI - Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers JO - Hepatology VL - 47 UR - https://doi.org/10.1002/hep.21984 DO - 10.1002/hep.21984 ID - Guha2008 ER - TY - JOUR AU - Rodriguez-Suarez, E. AU - Duce, A. M. AU - Caballeria, J. PY - 2010 DA - 2010// TI - Non-alcoholic fatty liver disease proteomics JO - Proteomics Clin applications VL - 4 UR - https://doi.org/10.1002/prca.200900119 DO - 10.1002/prca.200900119 ID - Rodriguez-Suarez2010 ER - TY - JOUR AU - Charlton, M. AU - Viker, K. AU - Krishnan, A. PY - 2009 DA - 2009// TI - Differential expression of lumican and fatty acid binding protein-1: new insights into the histologic spectrum of nonalcoholic fatty liver disease JO - Hepatology VL - 49 UR - https://doi.org/10.1002/hep.22927 DO - 10.1002/hep.22927 ID - Charlton2009 ER - TY - JOUR AU - Shiha, G. AU - Ibrahim, A. AU - Helmy, A. PY - 2017 DA - 2017// TI - Asian-Pacific Association for the Study of the Liver (APASL) consensus guidelines on invasive and non-invasive assessment of hepatic fibrosis: a 2016 update JO - Hepatol Int VL - 11 UR - https://doi.org/10.1007/s12072-016-9760-3 DO - 10.1007/s12072-016-9760-3 ID - Shiha2017 ER - TY - JOUR AU - Goodman, Z. D. PY - 2014 DA - 2014// TI - The impact of obesity on liver histology JO - Clin Liver Dis VL - 18 UR - https://doi.org/10.1016/j.cld.2013.09.010 DO - 10.1016/j.cld.2013.09.010 ID - Goodman2014 ER - TY - JOUR AU - Bedossa, P. PY - 2016 DA - 2016// TI - Histological Assessment of NAFLD JO - Dig Dis Sci VL - 61 UR - https://doi.org/10.1007/s10620-016-4062-0 DO - 10.1007/s10620-016-4062-0 ID - Bedossa2016 ER - TY - JOUR AU - Luchini, A. AU - Geho, D. H. AU - Bishop, B. PY - 2008 DA - 2008// TI - Smart hydrogel particles: biomarker harvesting: one-step affinity purification, size exclusion, and protection against degradation JO - Nano letters VL - 8 UR - https://doi.org/10.1021/nl072174l DO - 10.1021/nl072174l ID - Luchini2008 ER - TY - JOUR AU - Longo, C. AU - Patanarut, A. AU - George, T. PY - 2009 DA - 2009// TI - Core-shell hydrogel particles harvest, concentrate and preserve labile low abundance biomarkers JO - PloS one VL - 4 UR - https://doi.org/10.1371/journal.pone.0004763 DO - 10.1371/journal.pone.0004763 ID - Longo2009 ER - TY - JOUR AU - Tamburro, D. AU - Fredolini, C. AU - Espina, V. PY - 2011 DA - 2011// TI - Multifunctional core-shell nanoparticles: discovery of previously invisible biomarkers JO - J Am Chem Soc VL - 133 UR - https://doi.org/10.1021/ja207515j DO - 10.1021/ja207515j ID - Tamburro2011 ER - TY - JOUR AU - Zhou, W. AU - Capello, M. AU - Fredolini, C. PY - 2011 DA - 2011// TI - Proteomic analysis of pancreatic ductal adenocarcinoma cells reveals metabolic alterations JO - J Proteome Res VL - 10 UR - https://doi.org/10.1021/pr101179t DO - 10.1021/pr101179t ID - Zhou2011 ER - TY - JOUR AU - Signore, M. AU - Reeder, K. A. PY - 2012 DA - 2012// TI - Antibody validation by Western blotting JO - Methods Mol Biol VL - 823 UR - https://doi.org/10.1007/978-1-60327-216-2_10 DO - 10.1007/978-1-60327-216-2_10 ID - Signore2012 ER - TY - JOUR AU - Paweletz, C. P. AU - Charboneau, L. AU - Bichsel, V. E. PY - 2001 DA - 2001// TI - Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front JO - Oncogene VL - 20 UR - https://doi.org/10.1038/sj.onc.1204265 DO - 10.1038/sj.onc.1204265 ID - Paweletz2001 ER - TY - JOUR AU - Einspahr, J. G. AU - Calvert, V. AU - Alberts, D. S. PY - 2012 DA - 2012// TI - Functional protein pathway activation mapping of the progression of normal skin to squamous cell carcinoma JO - Cancer Prev Res VL - 5 UR - https://doi.org/10.1158/1940-6207.CAPR-11-0427 DO - 10.1158/1940-6207.CAPR-11-0427 ID - Einspahr2012 ER - TY - JOUR AU - Akbani, R. AU - Becker, K. F. AU - Carragher, N. PY - 2014 DA - 2014// TI - Realizing the promise of reverse phase protein arrays for clinical, translational, and basic research: a workshop report: the RPPA (Reverse Phase Protein Array) society JO - Mol Cell Proteomics VL - 13 UR - https://doi.org/10.1074/mcp.O113.034918 DO - 10.1074/mcp.O113.034918 ID - Akbani2014 ER - TY - JOUR AU - Rapkiewicz, A. AU - Espina, V. AU - Zujewski, J. A. PY - 2007 DA - 2007// TI - The needle in the haystack: application of breast fine-needle aspirate samples to quantitative protein microarray technology JO - Cancer VL - 111 UR - https://doi.org/10.1002/cncr.22686 DO - 10.1002/cncr.22686 ID - Rapkiewicz2007 ER - TY - JOUR AU - Manyam, G. AU - Birerdinc, A. AU - Baranova, A. PY - 2015 DA - 2015// TI - KPP: KEGG Pathway Painter JO - BMC Syst Biol VL - 9 UR - https://doi.org/10.1186/1752-0509-9-S2-S3 DO - 10.1186/1752-0509-9-S2-S3 ID - Manyam2015 ER - TY - JOUR AU - Vega, M. I. AU - Huerta-Yepaz, S. AU - Garban, H. PY - 2004 DA - 2004// TI - Rituximab inhibits p38 MAPK activity in 2F7 B NHL and decreases IL-10 transcription: pivotal role of p38 MAPK in drug resistance JO - Oncogene VL - 23 UR - https://doi.org/10.1038/sj.onc.1207336 DO - 10.1038/sj.onc.1207336 ID - Vega2004 ER - TY - JOUR AU - Guo, X. AU - Harada, C. AU - Namekata, K. PY - 2010 DA - 2010// TI - Regulation of the severity of neuroinflammation and demyelination by TLR-ASK1-p38 pathway JO - EMBO Mol Med VL - 2 UR - https://doi.org/10.1002/emmm.201000103 DO - 10.1002/emmm.201000103 ID - Guo2010 ER - TY - JOUR AU - Peifer, C. AU - Wagner, G. AU - Laufer, S. PY - 2006 DA - 2006// TI - New approaches to the treatment of inflammatory disorders small molecule inhibitors of p38 MAP kinase JO - Curr Top Med Chem VL - 6 UR - https://doi.org/10.2174/156802606775270323 DO - 10.2174/156802606775270323 ID - Peifer2006 ER - TY - JOUR AU - Zhang, J. AU - Shen, B. AU - Lin, A. PY - 2007 DA - 2007// TI - Novel strategies for inhibition of the p38 MAPK pathway JO - Trends Pharmacol Sci VL - 28 UR - https://doi.org/10.1016/j.tips.2007.04.008 DO - 10.1016/j.tips.2007.04.008 ID - Zhang2007 ER - TY - JOUR AU - Schreiber, S. AU - Feagan, B. AU - D’Haens, G. PY - 2006 DA - 2006// TI - Oral p38 mitogen-activated protein kinase inhibition with BIRB 796 for active Crohn’s disease: a randomized, double-blind, placebo-controlled trial JO - Clin Gastroenterol Hepatol VL - 4 UR - https://doi.org/10.1016/j.cgh.2005.11.013 DO - 10.1016/j.cgh.2005.11.013 ID - Schreiber2006 ER - TY - JOUR AU - Ratziu, V. AU - Sheikh, M. Y. AU - Sanyal, A. J. PY - 2012 DA - 2012// TI - A phase 2, randomized, double-blind, placebo-controlled study of GS-9450 in subjects with nonalcoholic steatohepatitis JO - Hepatology VL - 55 UR - https://doi.org/10.1002/hep.24747 DO - 10.1002/hep.24747 ID - Ratziu2012 ER - TY - JOUR AU - Hu, X. AU - Chen, J. AU - Wang, L. PY - 2007 DA - 2007// TI - Crosstalk among Jak-STAT, Toll-like receptor, and ITAM-dependent pathways in macrophage activation JO - J Leukocyte Biol VL - 82 UR - https://doi.org/10.1189/jlb.1206763 DO - 10.1189/jlb.1206763 ID - Hu2007 ER - TY - JOUR AU - Baker, S. S. AU - Baker, R. D. AU - Liu, W. PY - 2010 DA - 2010// TI - Role of alcohol metabolism in non-alcoholic steatohepatitis JO - PloS One VL - 5 UR - https://doi.org/10.1371/journal.pone.0009570 DO - 10.1371/journal.pone.0009570 ID - Baker2010 ER - TY - JOUR AU - Zhu, L. AU - Baker, S. S. AU - Gill, C. PY - 2013 DA - 2013// TI - Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH JO - Hepatology VL - 57 UR - https://doi.org/10.1002/hep.26093 DO - 10.1002/hep.26093 ID - Zhu2013 ER - TY - JOUR AU - Zhu, R. AU - Baker, S. S. AU - Moylan, C. A. PY - 2016 DA - 2016// TI - Systematic transcriptome analysis reveals elevated expression of alcohol-metabolizing genes in NAFLD livers JO - J Pathol VL - 238 UR - https://doi.org/10.1002/path.4650 DO - 10.1002/path.4650 ID - Zhu2016 ER - TY - JOUR AU - Plompen, E. P. AU - Schouten, J. N. AU - Janssen, H. L. PY - 2013 DA - 2013// TI - Role of anticoagulant therapy in liver disease JO - Hepatol Int VL - 7 UR - https://doi.org/10.1007/s12072-013-9427-2 DO - 10.1007/s12072-013-9427-2 ID - Plompen2013 ER - TY - JOUR AU - Plompen, E. P. AU - Darwish Murad, S. AU - Hansen, B. E. PY - 2015 DA - 2015// TI - Prothrombotic genetic risk factors are associated with an increased risk of liver fibrosis in the general population: The Rotterdam Study JO - J Hepatol VL - 63 UR - https://doi.org/10.1016/j.jhep.2015.07.026 DO - 10.1016/j.jhep.2015.07.026 ID - Plompen2015 ER - TY - JOUR AU - Perry, R. J. AU - Samuel, V. T. AU - Petersen, K. F. PY - 2014 DA - 2014// TI - The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes JO - Nature VL - 510 UR - https://doi.org/10.1038/nature13478 DO - 10.1038/nature13478 ID - Perry2014 ER - TY - JOUR AU - Inoue, H. AU - Ogawa, W. AU - Ozaki, M. PY - 2004 DA - 2004// TI - Role of STAT-3 in regulation of hepatic gluconeogenic genes and carbohydrate metabolism in vivo JO - Nature Med VL - 10 UR - https://doi.org/10.1038/nm980 DO - 10.1038/nm980 ID - Inoue2004 ER - TY - JOUR AU - Moh, A. AU - Zhang, W. AU - Yu, S. PY - 2008 DA - 2008// TI - STAT3 sensitizes insulin signaling by negatively regulating glycogen synthase kinase-3 beta JO - Diabetes VL - 57 UR - https://doi.org/10.2337/db06-1582 DO - 10.2337/db06-1582 ID - Moh2008 ER - TY - STD TI - Golabi P, Stepanova M, Pham HT, Cable R, Rafiq N, Bush H, Gogoll T, Younossi ZM. Non-alcoholic steatofibrosis (NASF) can independently predict mortality in patients with non-alcoholic fatty liver disease (NAFLD). BMJ Open Gastroenterol. 2018;5(1):e000198. https://doi.org/10.1136/bmjgast-2018-000198. eCollection 2018. ID - ref57 ER -